Mirap (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors, further enhancing serotonergic transmission while reducing certain side‑effects associated with serotonin activation.

The appropriate dose of Mirap is determined by the prescribing clinician based on the patient’s age, clinical condition, and response to therapy. Dosage adjustments may be made during treatment, and the prescriber will provide specific instructions tailored to each individual.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Mirap, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism that includes α2‑adrenergic antagonism and strong antihistaminic activity, often resulting in sedation and weight gain. It may be preferred when insomnia or appetite stimulation is clinically desirable, but individual response varies.

Mirap should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mirap is taken orally, usually once daily in the evening to take advantage of its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for any signs of these conditions, and immediate medical attention is required if they occur.

Mirap is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in individuals currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days. Caution is also advised for patients with severe hepatic impairment.